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ABSTRACT 
Background: Different diagnostic interviews are used as reference standards for major 
depression classification in research. Semi-structured interviews involve clinical judgement, 
whereas fully structured interviews are completely scripted. The Mini International 
Neuropsychiatric Interview (MINI), a brief fully structured interview, is also sometimes used. It 
is not known whether interview method is associated with probability of major depression 
classification. Aims: To evaluate the association between interview method and odds of major 
depression classification, controlling for depressive symptom scores and participant 
characteristics. Method: Data collected for an individual participant data meta-analysis of 
Patient Health Questionnaire-9 (PHQ-9) diagnostic accuracy were analyzed. Binomial 
Generalized Linear Mixed Models were fit. Results: 17,158 participants (2,287 major depression 
cases) from 57 primary studies were analyzed. Among fully structured interviews, odds of major 
depression were higher for the MINI compared to the Composite International Diagnostic 
Interview (CIDI) [OR (95% CI) = 2.10 (1.15-3.87)]. Compared to semi-structured interviews, 
fully structured interviews (MINI excluded) were non-significantly more likely to classify 
participants with low-level depressive symptoms (PHQ-9 scores 6) as having major depression 
[OR (95% CI) = 3.13 (0.98-10.00)], similarly likely for moderate-level symptoms (PHQ-9 scores 
7-15) [OR (95% CI) = 0.96 (0.56-1.66)], and significantly less likely for high-level symptoms 
(PHQ-9 scores 16) [OR (95% CI) = 0.50 (0.26-0.97)]. Conclusions: The MINI may identify 
more depressed cases than the CIDI, and semi- and fully structured interviews may not be 
interchangeable methods, but these results should be replicated. Declaration of Interest: This 
study was funded by the Canadian Institutes of Health Research (KRS-134297).  
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INTRODUCTION 
Historically, major depression classification in research was done by clinical judgement or 
unstructured interviews. Lack of agreement between interviewers led to the development of 
standardized diagnostic interviews, including semi-structured interviews, designed to be 
administered by clinicians, and fully structured interviews, which can be administered by lay 
interviewers.1,2 Semi-structured interviews are akin to a guided diagnostic conversation. 
Standardized questions are asked, but interviewers may insert additional queries and use clinical 
judgement to decide whether symptoms are present.2,3 Examples include the Structured Clinical 
Interview for DSM (SCID) and Schedules for Clinical Assessment in Neuropsychiatry 
(SCAN).4,5 In contrast, fully structured interviews typically involve fully scripted, standardized 
questions that are read verbatim, without additional probes.2,3 They are designed to be less 
subjective and provide greater standardization, but with less flexibility and without incorporating 
clinical judgment.2,3,6 Examples include the Composite International Diagnostic Interview (CIDI) 
and the Diagnostic Interview Schedule (DIS).7,8 The Mini International Neuropsychiatric 
Interview (MINI) is also a fully structured interview, but it differs from the CIDI and DIS in that 
it was described by its authors as designed to be able to be administered in a fraction of the time 
at the cost of being over-inclusive and generating a higher rate of false-positive diagnoses.9,10 
Although fully structured interviews are sometimes referred to as imperfect reference 
standards compared to semi-structured interviews,11 both are considered appropriate reference 
standards for major depression classification in research.2 Consistent with this, existing meta-
analyses on depression screening tool accuracy have treated both interview types as equivalent 
reference standards.12 For different interviews to be treated as equivalent diagnostic standards, 
the probability of being classified as meeting diagnostic criteria should not depend on the 
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interview administered. Different interview formats, however, may lead to different diagnostic 
patterns. For instance, it is possible that the greater standardization and reliability across 
interviews gained in fully structured interviews, compared to clinician-administered semi-
structured interviews, could increase misclassification.  
Five studies have administered validated semi- and fully structured interviews to the same 
set of participants in non-psychiatric settings within a 2-week period to assess current major 
depression (SupplementaryTable1).11,13–16 Most included small numbers of participants and 
major depression cases. Nonetheless, in the three studies with ≥100 participants, prevalence of 
major depression was more than twice as high when assessed with fully structured interviews 
compared to semi-structured interviews. No studies have randomized participants to receive 
either a fully or semi-structured interview and compared major depression prevalence. 
The high cost and burden of administering multiple diagnostic interviews to large numbers 
of participants or, alternatively, randomizing large numbers of participants to receive semi- or 
fully structured interviews, presents a substantial barrier to testing for differences between 
interview types. An alternative would be to compare the probability of being classified as having 
major depression using different interview types, controlling for depression symptom severity 
and other factors potentially related to classification. Individual participant data (IPD) meta-
analysis, in which participant-level data from many studies are synthesized, offers a way to 
examine the association between diagnostic method and probability of major depression 
classification across a large number of participants, controlling for factors potentially associated 
with classification, including depressive symptom severity. 
The objective of this study was to examine the association between diagnostic interview 
method and major depression classification. First, we compared the odds of major depression 
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classification using different diagnostic interviews, first among semi-structured interviews and 
then separately among fully structured interviews, in each case controlling for depressive 
symptom severity and study- and participant-level characteristics. Second, we compared the odds 
of major depression classification between the semi- and fully structured interviews, including a 
focus on the interviews with the largest numbers of patients, the SCID and the CIDI, and 
controlling for depressive symptom severity and study and participant-level characteristics. 
Third, we tested whether differences in the odds of classification across interview types were 
associated with depressive symptom severity. 
METHOD 
This study used data accrued for an IPD meta-analysis on the diagnostic accuracy of the 
Patient Health Questionnaire-9 (PHQ-9) depression screening tool to detect major depression. 
Detailed methods were registered in PROSPERO (CRD42014010673), and a protocol was 
published.17 As an initial step, we assessed the comparability of diagnostic classifications 
generated by different diagnostic interviews. 
Search Strategy 
A medical librarian searched Medline, Medline In-Process & Other Non-Indexed 
Citations, PsycINFO, and Web of Science from January 2000 - December 2014 on February 7, 
2015, using a search strategy (SupplementaryMethods1), which was peer-reviewed using 
PRESS.18 We limited our search to these databases based on research showing that adding other 
databases when the Medline search is highly sensitive does not identify additional eligible 
studies.19 The search was limited to the year 2000 forward because the PHQ-9 was published in 
2001.20 We reviewed reference lists of relevant reviews and queried contributing authors about 
non-published studies. Search results were uploaded into RefWorks (RefWorks-COS, Bethesda, 
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MD, USA). After de-duplication, unique citations were uploaded into DistillerSR (Evidence 
Partners, Ottawa, Canada), which was used to store and track search results and track the review 
process. 
Identification of Eligible Studies 
Datasets from articles in any language were eligible for inclusion if they included 
diagnostic classification for current Major Depressive Disorder (MDD) or Major Depressive 
Episode (MDE) based on a validated semi- or fully structured interview conducted within two 
weeks of PHQ-9 administration, since diagnostic criteria are for symptoms in the last two weeks. 
Datasets where not all participants were administered the PHQ-9 within two weeks of the 
diagnostic interview were included if the primary data allowed us to select participants 
administered the diagnostic interview and PHQ-9 within two weeks. Data from studies where the 
PHQ-9 was administered exclusively to patients known to have psychiatric diagnoses or 
symptoms were excluded, since screening is not done with patients already managed in 
psychiatric settings.21 For defining major depression, we considered MDD or MDE based on the 
Diagnostic and Statistical Manual of Mental Disorders (DSM), or MDE based on the 
International Classification of Diseases (ICD). If more than one was reported, we prioritized 
DSM over ICD, and DSM MDE over DSM MDD. We prioritized MDE over MDD because 
screening tests are intended to identify symptoms of depression and not rule out due to bipolar 
disorder. We prioritized DSM over ICD because DSM is more commonly used in existing 
studies. However, across all studies, there were only 23 discordant diagnoses that depended on 
classification prioritization (0.1% of participants). 
Two investigators independently reviewed titles and abstracts for eligibility. If either 
reviewer deemed a study potentially eligible, a full-text article review was completed, also by 
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two investigators independently. Seven members of the research team participated in the review 
process; however, each title and abstract and each full text was reviewed independently by only 
two of the seven investigators. Disagreement between reviewers after full-text review was 
resolved by consensus, including a third investigator (either BL or BDT) when necessary. Titles, 
abstracts and full-text articles in languages other than English were translated by members of the 
research team or by advanced research trainees who were native speakers of the language and 
familiar with the topic. They were not paid for their translation services. 
Data Contribution and Synthesis 
Authors of eligible datasets were invited to contribute de-identified primary data. Primary 
study country, clinical setting, language, and diagnostic interview administered were extracted 
from published reports by two investigators independently, with disagreements resolved by 
consensus. Countries were categorized as “very high”, “high”, or “low-medium” development 
level based on the United Nation’s human development index.22 Recruitment settings were 
categorized as “non-medical”, “primary care”, “inpatient specialty care”, or “outpatient specialty 
care”. Participant-level data included age, sex, major depression status, and PHQ-9 scores. In 
three primary studies, multiple settings were included, thus setting was coded at the participant-
level. 
Individual participant data were converted to a standard format and entered into a single 
dataset that also included study-level data. We compared published participant characteristics 
and diagnostic accuracy results with results obtained using the raw datasets. When primary data 
and original publications were discrepant, we identified and corrected errors when possible, and 
resolved outstanding discrepancies in consultation with the original investigators. Two 
investigators assessed risk of bias of included studies independently, using the Quality 
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Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool.23 See 
SupplementaryMethods2 for QUADAS-2 coding rules. Discrepancies in data extraction and risk 
of bias assessment were resolved by consensus.  
Statistical Analyses 
To isolate the association between diagnostic assessment method and major 
depression classification, we estimated binomial Generalized Linear Mixed Models 
(GLMMs) with a logit link function. In all analyses, the outcome was major depression 
classification. The predictor of interest was either the specific diagnostic interview or 
interview category, depending on the analysis. Covariates were depressive symptom 
severity (PHQ-9 score), age, sex, country human development index, and clinical 
setting. The PHQ-9 has been shown in many studies, across diverse populations in both 
medical and non-medical settings, to be a valid measure of depressive symptom severity 
with good convergent validity and a one-dimensional factor structure.20,24–27 Other 
covariates were chosen due to their potential influence on major depression 
classification and their availability across primary studies. To account for correlation 
between subjects within the same primary study, a random intercept was fit for each 
primary study. Fixed slopes were estimated for PHQ-9 score, assessment method, age, 
sex, human development index, and clinical setting.  
First, we estimated a GLMM among studies that used semi-structured interviews 
(SCID, SCAN, Depression Interview and Structured Hamilton [DISH]). Then, we 
estimated a GLMM among studies that used fully structured interviews (CIDI, Clinical 
Interview Schedule-Revised [CIS-R], Diagnostic Interview Schedule [DIS], MINI). For 
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each model, we used the interview with the greatest number of participants as the 
reference category. 
Second, because the MINI was intentionally designed to be a brief, but overly 
inclusive, tool,9,10 and based on results from the first analyses, which were consistent 
with this, we compared fully structured diagnostic interviews, without the MINI, to 
semi-structured interviews. To do this, we estimated a GLMM to compare odds of 
major depression classification between the remaining semi- and fully structured 
interviews, (reference = semi-structured). As a sensitivity analysis, we further restricted 
our analysis to studies using either the CIDI or SCID (reference = SCID), as these 
interviews were used substantially more often than other included interviews. 
Third, we investigated a possible interaction between interview assessment 
method and depressive symptom severity based on categorical PHQ-9 score 
classifications. To do this, we separated PHQ-9 scores into 3 categories: low (scores 0-
6; reference group), medium (scores 7-15), and high (scores 16-27). Score ranges were 
chosen because recent meta-analyses of the PHQ-9 have evaluated cutoff scores from 7 
to 15, suggesting a mid-level range.28 To compare models with and without the 
interaction term, a likelihood ratio test was used. We then replicated the model 
comparing semi- and fully structured interviews in each PHQ-9 category separately to 
obtain stratum-specific classification odds ratios for fully versus semi-structured 
interviews. Additionally, we conducted a separate interaction analysis between 
continuous PHQ-9 score and diagnostic interview method. As a sensitivity analysis, we 
further restricted our interaction analyses to studies using the CIDI or SCID. 
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In another set of sensitivity analyses, we reran all of our models adding domain 
scores for QUADAS-2. All analyses were run in R using the lme4 package.  
Funding and ethics 
The study sponsors had no role in study design; in the collection, analysis, and 
interpretation of data; in the writing of the report; or in the decision to submit the paper 
for publication. BDT had full access to all data in the study and had final responsibility 
for the decision to submit for publication. As this study involved secondary analysis of 
anonymized previously collected data, the Research Ethics Committee of the Jewish 
General Hospital declared that this project did not require research ethics approval. 
However, for each included dataset, we confirmed that the original study received 
ethics approval and that all patients provided informed consent. 
RESULTS 
Search Results and Inclusion of Primary Data 
Of 5,248 unique titles and abstracts identified from the database search, 5,039 were 
excluded after title and abstract review and 113 after full-text review, leaving 96 eligible articles 
with data from 69 unique participant samples (SupplentaryFigure1). Of the 69 unique samples, 
55 contributed data (80%). In addition, authors of included studies contributed data from three 
unpublished studies, for a total of 58 datasets. However, one primary dataset did not include data 
for key covariates included in analyses and was excluded, leaving 57 primary datasets. In total, 
17,158 participants (2,287 major depression cases) were included. Included study characteristics 
are shown in SupplementaryTable2a. Characteristics of eligible studies that did not provide data 
for the present study are shown in SupplementaryTable2b. Of the 21,171 participants in 69 
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eligible published datasets, 16,757 were in the 54 published studies with data included in the 
present study (79%). 
Of the 57 total included studies, 29 used semi-structured interviews, and 28 used fully 
structured interviews (Table 1). The SCID was the most commonly used semi-structured 
interview (26 studies, 4,732 participants), and the CIDI (11 studies, 6,271 participants) and MINI 
(14 studies, 2,756 participants) were the most commonly used fully structured interviews.  
Association of Diagnostic Interview and Major Depression Classification 
Semi-structured Interviews 
Among semi-structured interviews, compared to the SCID, odds of major depression 
were not significantly different for the SCAN (adjusted odds ratio [aOR] = 0.56, 95% confidence 
interval [95% CI] = 0.18 to 1.78) or DISH (aOR = 1.13, 95% CI = 0.19 to 6.80). However, only 
two studies used the SCAN, and only one used the DISH. 
Fully Structured Interviews 
Among fully structured interviews, compared to the CIDI, odds of major depression were 
higher, but not significantly different for the DIS (aOR = 4.32, 95% CI = 0.95 to 19.62) or CIS-R 
(aOR = 1.53, 95% CI = 0.48 to 4.91), although these estimates were based on one and two 
studies, respectively. Participants interviewed with the MINI were substantially and statistically 
significantly more likely to be classified as having major depression (aOR = 2.10, 95% CI = 1.15 
to 3.87).  
Semi-structured versus Fully Structured Interviews  
Excluding the MINI, odds of major depression were similar using fully versus semi-
structured interviews (aOR = 0.90, 95% CI = 0.51 to 1.57). In a sensitivity analysis restricted to 
studies that used the SCID or CIDI, odds of major depression were lower for the CIDI compared 
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to the SCID, but this was not statistically significantly different (aOR = 0.57, 95% CI = 0.32 to 
1.02).   
Interaction between PHQ-9 Scores and Diagnostic Interview Method 
The proportion of participants classified as having major depression at each PHQ-9 score 
for semi-structured interviews, fully structured interviews (MINI excluded), and the MINI are 
shown in Figure 1a, with differences in proportions across interview types shown in Figure 1b. 
As shown in Figure 1 and SupplementaryTable3, compared to semi-structured interviews, fully 
structured interviews resulted in a somewhat higher probability of major depression 
classification for PHQ-9 scores from 0 to 10, but lower probability for PHQ-9 scores of 11 to 27. 
Consistent with this, there was a significant interaction between assessment method and PHQ-9 
score category (Table 2), and the likelihood ratio test comparing models with and without the 
interaction term was statistically significant (p < 0.001). The interaction was also statistically 
significant when tested using the PHQ-9 as a continuous variable. The aOR for the interaction 
between PHQ-9 score and fully structured interview was 0.90 (95% CI = 0.88 to 0.92), which 
suggested a 10% dilution in the slope of the odds of a major depression diagnosis across PHQ-9 
scores for fully structured interviews compared to semi-structured interviews. 
When stratified based on PHQ-9 score category, participants with low PHQ-9 scores (0-6) 
were more likely to receive a major depression classification with a fully structured interview 
compared to a semi-structured interview (aOR = 3.13, 95% CI = 0.98 to 10.00), although this 
was not statistically significant. Semi- and fully structured interviews performed similarly among 
participants in the medium PHQ-9 group (scores 7-15: aOR = 0.96, 95% CI = 0.56 to 1.66). 
Among participants with high PHQ-9 scores (16-27), participants were significantly less likely to 
be classified with major depression using fully structured interviews (aOR = 0.50, 95% CI = 0.26 
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to 0.97, Table 3). These odds ratios corresponded to a crude prevalence of 3.2% among those 
administered a fully structured interview vs. 1.2% among those administered a semi-structured 
interview in the low range PHQ-9 group, 21.4% vs. 20.8% in the medium range group, and 
54.2% vs. 72.5% in the high range group, not adjusting for PHQ-9 scores or participant 
characteristics.  
In sensitivity analyses restricted to studies that used the SCID or CIDI, results for 
interaction models were similar. 
Risk of Bias Sensitivity Analyses  
See SupplentaryTable4 for QUADAS-2 ratings for each included primary study. In 
sensitivity analyses with models that included QUADAS-2 domains, no domains were 
significantly associated with major depression, and the inclusion of the QUADAS-2 domains did 
not substantially change coefficient estimates for any variables.  
DISCUSSION 
There were two main findings. First, among fully structured interviews, the adjusted odds 
of being classified as having major depression were approximately twice as high using the MINI 
compared to the CIDI. Second, excluding the MINI, there was a statistically significant 
interaction between fully structured versus semi-structured interview and depression symptom 
severity based on the PHQ-9. Compared to semi-structured interviews, the likelihood of 
diagnosis increased significantly less for fully structured interviews as symptom severity 
increased. Fully structured interviews tended to classify more participants with low-level 
symptoms as having major depression, although this was not statistically significant; they 
performed similar to semi-structured interviews for participants with moderate symptoms, and 
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they classified fewer participants with high-level symptoms as having major depression 
compared to semi-structured interviews. 
The finding that odds of major depression classification were twice as high for the MINI 
compared to the CIDI is consistent with the interviews’ designs. Whereas the CIDI and other 
fully structured interviews are in-depth interviews,7,8 the MINI was developed to be able to be 
administered in a fraction of the time as other interviews and was described by its developers as 
designed to be over-inclusive.9,10 Our findings suggest that, consistent with the developers’ 
intent, the MINI may identify substantially higher rates of major depression if used to determine 
case status than other fully structured interviews. The probability of being classified with major 
depression was also high based on the DIS and CIS-R, but evidence was too limited to draw 
conclusions. The formats of these interviews, however, are more similar to the CIDI than the 
MINI. 
By standardizing all questions and probes and removing clinical judgment, fully structured 
interviews are designed to be as reliable as possible, but this may reduce advantages of semi-
structured interviews related to the inclusion of a framework for incorporating clinical judgment. 
Consistent with this, our findings suggest that compared to semi-structured interviews, the 
association between symptom levels and probability of being classified as having major 
depression was lower for fully structured interviews (MINI excluded). Compared to semi-
structured interviews, participants with low-level depressive symptoms assessed with fully 
structured interviews appeared more likely to be classified as having major depression, whereas 
participants with high-level symptoms appeared less likely. Participants with moderate 
symptoms were similarly likely to be classified as having major depression when semi- and fully 
structured interviews were used. This suggests that, in practice, the effect of the diagnostic 
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interview that is selected on the prevalence that is generated likely depends on the underlying 
distribution of symptom levels in the population. 
Existing data from other studies is roughly consistent with this. In general population 
samples, where depressive symptom levels are generally low, major depression prevalence has 
been found to be substantially higher when fully structured interviews are used versus semi-
structured interviews (SupplementaryTable1).11,13 On the other hand, in a study of patients from 
an alcoholic treatment unit, where depressive symptoms would be expected to be much higher, 
major depression prevalence was similar based on semi- and fully structured interviews.15 
In research settings, semi- and fully structured interviews are typically used 
interchangeably as appropriate reference standards in depression screening tool diagnostic 
accuracy studies, for inclusion and exclusion in treatment trials, and for determining major 
depression prevalence. Based on the findings of the present study, caution is warranted when 
deciding which interview to use. Prevalence estimates may be influenced, potentially 
substantially, by this choice. It is not clear to what degree estimates of screening tool accuracy 
may be influenced by using a fully versus semi-structured interview, and this should be 
determined by future studies, including a replication of this study using data from IPD meta-
analyses of other depression screening tools.29,30  
This is the first study to compare fully and semi-structured interviews for major depression 
using an IPD meta-analysis approach. Strengths of this study include the large overall sample 
size and the ability to consider both study and participant-level factors in analyses, including 
participant-specific depressive symptom severity. There are also limitations to consider. First, we 
were unable to include primary data from 15 of 69 eligible datasets (20% of eligible datasets, 
21% of eligible participants), and we restricted our analyses to those with complete data for all 
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variables in our models (98% of available data). Nonetheless, this was a very large sample, many 
times the size of existing studies that have attempted to compare fully and semi-structured 
interviews for major depression. None of those studies included more than 61 cases based on a 
fully structured interview or 22 cases based on a semi-structured interview. Second, despite the 
large overall sample size, there was substantial heterogeneity across studies. We were not able to 
conduct subgroup analyses based on medical comorbidity or cultural aspects such as country or 
language because comorbidity data were not available for over half of participants, and many 
countries and languages were represented in few primary studies. However, studies of 
differential item functioning with the PHQ-9 have shown that it performs equivalently across 
multiple languages and between people with and without medical disorders.31–35 Third, it is 
possible that residual confounding may exist, given that we were only able to consider variables 
collected in the original investigations, and the included study-level variables may not apply 
uniformly to all participants in a study. Fourth, although we coded for the qualifications of the 
interviewer for all semi-structured interviews as part of our QUADAS-2 rating, two studies used 
interviewers who did not meet typical standards, and approximately half of studies were rated 
unclear. This may have influenced the quality of the reference standard in some studies. Fifth, 
particularly for semi-structured interviews, lack of interviewer blinding may have influenced 
classifications. Although only two studies were coded as having non-blinded interviewers, 11 
were coded as unclear. We did not query authors on interviewer characteristics and blinding if 
information was not published due to concern that recollection, in some cases, after over a 
decade had passed, may not have been accurate.  
CONCLUSIONS 
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We found that the MINI diagnostic interview was associated with a substantially higher 
probability of major depression classification than the CIDI, controlling for depression symptom 
scores on the PHQ-9 and other patient characteristics. We also found that compared to semi-
structured interviews, fully structured interviews tend to classify more people with low-level 
symptoms as depressed, but fewer people with high-level symptoms. This suggests that the 
choice of using a fully structured diagnostic interview or a semi-structured interviews may 
influence research findings. This is the first study that has used a large participant sample and 
IPD meta-analysis to compare diagnostic interview methods, and future research should replicate 
this study to verify results. 
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FIGURES 
 
Figure 1a. Probability of Major Depression Classification by PHQ-9 Score for Semi-
structured Interviews, Fully structured Interviews (Excluding MINI), and MINI.  
 
Proportions are plotted as 3-point moving averages (e.g., the proportions at the PHQ-9 score of 10 are 
averages of the proportions at PHQ-9 scores of 9, 10, and 11). 
 
 51 
Figure 1b. Difference in Probability of Major Depression Classification by PHQ-9 
Score for Semi-structured Interviews and MINI compared to Fully structured Interviews 
(Excluding MINI).  
 
Differences in proportions are plotted as 3-point moving averages (e.g., the differences in proportions at 
the PHQ-9 score of 10 are averages of the differences in proportions at PHQ-9 scores of 9, 10, and 11). 
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Table 1. Participant data by diagnostic interview 
Diagnostic Interview N Studies N Participants 
Major Depression 
N % 
Semi-structured     
SCID 26 4,732 785 17 
SCAN 2 1,891 130 7 
DISH 1 100 9 9 
Fully structured     
CIDI 11 6,271 554 9 
DIS 1 1,006 221 22 
MINI 14 2,756 524 19 
CIS-R 2 402 64 16 
Total 57 17,158 2,287 13 
Abbreviations: CIDI: Composite International Diagnostic Interview, CIS-R: Clinical Interview 
Schedule-Revised, DIS: Diagnostic Interview Schedule, DISH: Depression Interview and 
Structured Hamilton, MINI: Mini International Neuropsychiatric Interview, SCAN: Schedules for 
Clinical Assessment in Neuropsychiatry, SCID: Structured Clinical Interview for DSM Disorders
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Table 2. Model summary of fixed effects generalized linear mixed model 
considering a potential interaction between PHQ-9 score category and 
assessment methoda,b 
Variable 
Odds ratio (OR) 
OR 95% CI 
Fully structured assessment method 1.49  0.82-2.72 
PHQ-9 total score 1.37  1.35-1.40 
Age (years) 1.00  0.99-1.00 
Male sex 0.89  0.77-1.03 
Clinical setting -- -- 
Non-medical (reference) -- -- 
Primary care 0.67  0.27-1.64 
Specialty care: Inpatient 0.33  0.13-0.85 
Specialty care: Outpatient 0.64  0.26-1.54 
Human development index -- -- 
Very high (reference) -- -- 
High 2.27  1.11-4.61 
Low to medium 0.78  0.27-2.24 
PHQ-9 score category * fully structured assessment methodc -- -- 
Low PHQ-9 (0-6) (reference) -- -- 
Medium PHQ-9 (7-15) 0.73  0.57-0.92 
High PHQ-9 (16-27) 0.26  0.18-0.37 
aExcluding the MINI. 
bEstimate of random intercept variance = 0.58. 
cp < 0.001 in likelihood ratio test comparing models with and without interaction term. 
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Table 3. Generalized linear mixed model summaries for each PHQ-9 score category 
PHQ-9 score category 
Low PHQ scores (0-6) 
N = 9,339 
Medium PHQ scores (7-15) 
N = 3,970 
High PHQ scores (16-27) 
N = 1,093 
 OR 95% CI OR 95% CI OR 95% CI 
ORa (95% CI) for fully structured assessment method 3.13  0.98-10·00 0.96  0.56-1.66 0.50  0.26-0.97 
N receiving fully structured interview 5,228 1,999 452 
 N % N % N % 
N (%) with major depression 167 3.2 427 21.4 245 54.2 
N receiving semi-structured interview 4,111 1,971 641 
 N % N % N % 
N (%) with major depression 50 1.2 409 20.8 465 72.5 
aExcluding the MINI and adjusted for PHQ-9 score, age, sex, clinical setting and human development index. 
 
